Publications, posters & presentations -
our significant research

Filter
Research Area
Technology
Resource type
Category
89 results found
Apr 1, 2022
Clinical trial protocol
COVID-19
Current Protocol for Phase 3 Clinical Trial of NVX-CoV2373 in the U.S. and Mexico
Feb 21, 2022
Publication
Pre-print
COVID-19
First-in-Human Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
Keech, Cheryl, Glenn, Gregory M., Albert, Gary
Feb 21, 2022
Presentation
COVID-19
NVX-CoV2373 Vaccine for COVID-19

World Vaccine Congress Webinar

Glenn, Gregory
Feb 18, 2022
Poster
RSV
In-depth Analytical Characterization and Structural Modeling of Novavax RSV F Nanoparticle Vaccine

11th International Respiratory Syncytial Virus Symposium

Maynard, Ernest
Dec 25, 2021
Publication
Novavax led
Pre-print
COVID-19
Immunogenicity and Safety Following a Homologous Boosater Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled Trial
Mallory, Raburn, Formica, Neil, Pfeiffer, Susan, et al.
Dec 15, 2021
Publication
Novavax led
The New England Journal of Medicine
COVID-19
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico
Dunkle, Lisa M., Kotloff, Karen L., Gay, Cynthia L., et al.
Nov 23, 2021
Publication
Novavax included/third party
Frontiers in Immunology
COVID-19, Matrix-M™ adjuvant
Matrix M Adjuvanted H5aN1 Vaccine Elicits Broadly Neutralizing Antibodies and Neuraminidase Inhibiting Antibodies in Humans That Correlate With In Vivo Protection
Zhou, Fan, Hansen, Lena, Pedersen, Gabriel, et al.
Nov 17, 2021
Publication
Novavax led
The Lancet Respiratory Medicine
COVID-19, Seasonal influenza
Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial
Toback, Seth, Galiza, Eva, Cosgrove, Catherine, et al.
Oct 20, 2021
Presentation
COVID-19, Seasonal influenza
Update on Novavax NanoFlu™ vaccine and COVID-19-NanoFlu Combination Vaccine development

Presentation by Vivek Shinde, MD, MPH at the World Vaccine Congress Europe 2021. 

Shinde, Vivek
Oct 12, 2021
Publication
Novavax included/third party
Nature Partner Journals Vaccines
Preclinical development of a Pfs230-Pfs48/45 chimeric malaria transmission-blocking vaccine
Singh, Susheel K., Plieskatt, Jordan, Chourasia, Bishwanath K., et al.